Ocular Manifestations of Acquired Immunodeficiency Syndrome

Young Shin Kim¹, Hae Jung Sun¹, Tae Hyong Kim², Kui Dong Kang³, Sung Jin Lee¹

¹Department of Ophthalmology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea
²Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea
³Department of Ophthalmology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Incheon, Korea

Purpose: To investigate the patterns and risk factors of the ocular manifestations of acquired immunodeficiency syndrome (AIDS) and their correlation with CD4+ count in the era of highly active antiretroviral therapy (HAART).

Methods: This retrospective study examined 127 AIDS patients who presented to Soonchunhyang University Hospital. Data were collected from patient interviews, clinical examinations, and laboratory investigations. Ophthalmologic examinations included the best-corrected visual acuity, intraocular pressure, anterior segment and adnexal examination, and dilated fundus examination.

Results: Of the 127 patients with AIDS, 118 were on HAART and 9 were not. The mean CD4+ count was 266.7 ± 209.1 cells/μL. There were ocular manifestations in 61 patients (48.0%). The incidence of anterior segment manifestations was higher than posterior segment manifestations at 28.3% and 19.7%, respectively. The mean CD4+ count was significantly (p < 0.05) lower in the patients with posterior versus anterior segment ocular manifestations. The most common ocular manifestation was retinal microvasculopathy (15.0%), followed by keratoconjunctivitis sicca (14.2%), conjunctival microvasculopathy (9.4%), cytomegalovirus retinitis (3.1%), herpes zoster ophthalmicus (2.4%), and blepharitis (1.6%). Retinal microvasculopathy and cytomegalovirus retinitis were common in patients with CD4+ counts <200 cells/μL, while keratoconjunctivitis sicca and conjunctival microvasculopathy were common in patients with CD4+ counts of 200 to 499 cells/μL. There was a significant (p < 0.05) association between ocular manifestation and CD4+ count or age.

Conclusions: The introduction of HAART has changed the landscape of ocular presentations in patients with AIDS. In this study, anterior segment and external ocular manifestations occurred more frequently than posterior segment manifestations. Also, the mean CD4+ count was significantly lower in patients with posterior segment ocular manifestations versus anterior segment ocular manifestations. We found that CD4+ count and age >35 years were independent risk factors for developing ocular manifestations.

Key Words: Acquired immunodeficiency syndrome, CD4-positive T-lymphocytes, Eye manifestations, Highly active antiretroviral therapy

Since the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic began in 1981 [1], ocular involvement has been a common finding [2-4], and loss of vision is a serious problem in people living with HIV [5]. Before the era of highly active antiretroviral therapy (HAART), ocular involvement was...
estimated to develop in 50% to 75% of patients with HIV infection [6,7], including retinal microvasculopathy, vascular occlusions, opportunistic infections such as cytomegalovirus (CMV) retinitis, and progressive outer retinal necrosis [8]. A variety of other important AIDS-related manifestations involve the anterior segment, ocular surface, and adnexae [9].

The success of HAART in restoring CD4+ T-cell immunity has significantly affected the pattern and natural history of ocular manifestations of HIV infection [10]. The overall incidence of ocular manifestations of HIV infection in people living with HIV/AIDS has decreased to less than 40%. In the HAART era, there has been an estimated 80% decrease in the incidence of CMV retinitis [11]. With HAART, there have been improvements in the length [12] and quality of life of individuals with HIV. The incidence of sight-threatening complications has decreased, but attention should be still paid to other minor problems requiring ophthalmic care, including anterior segment and external ocular manifestations, which can affect the quality of life [2].

Therefore, this study describes the patterns and risk factors of the ocular manifestations of AIDS in the HAART era and their correlation to the CD4+ count.

Materials and Methods

A retrospective chart review was performed on patients seen at Soonchunhyang University Hospital from August 2004 to April 2014. Of 417 total HIV/AIDS patients, 127 were referred to the department of ophthalmology for an evaluation of ocular manifestations. Of these 127 patients, 118 were on HAART and 9 were not. Patients with additional medical problems such as diabetes mellitus, hypertension, and ocular trauma, which can have manifestations overlapping with AIDS, were excluded from the study.

Data were collected from patient interviews, clinical examinations, and laboratory investigations. Ophthalmologic examinations included the best-corrected visual acuity, intraocular pressure, anterior segment and adnexal examination, and dilated fundus examination.

Keratoconjunctivitis sicca was diagnosed using the Ocular Surface Disease Index (OSDI) questionnaire, which includes the following three domains: ocular symptoms, vision-related function, and environmental triggers [13]. Based on their OSDI scores, patients were categorized into two groups: those with a normal ocular surface (0 to 12 points) or those with ocular surface disease (≥13 points) [14]. Conjunctival microvasculopathy was diagnosed when patients presented with microaneurysms, segmental dilation of the venules, and adjacent narrowing of the arterioles, particularly with involvement of the inferior perilimbal bulbar conjunctiva [15].

Retinal microvasculopathy was diagnosed based on the following clinical manifestations: cotton-wool spots, microaneurysms, retinal hemorrhages, telangiectatic vascular changes, and the presence of capillary non-perfusion [16]. The diagnosis of CMV retinitis was based on clinical signs and symptoms [17-20]. CMV's characteristic retinal lesion has a dry appearing granular border surrounding an area of retinal edema and full-thickness retinal necrosis (Fig. 1).

The data were analyzed using IBM SPSS ver. 21 (IBM Corp., Armonk, NY, USA). Chi-square tests were used and p < 0.05 was considered significant. Student’s t-tests, Fisher’s exact tests, and multiple logistic regression were used to examine the associations and differences between the variables.

The study followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Soonchunhyang University.

Results

Of the 417 subjects with AIDS, 127 patients were assessed. The majority of patients (96.1%) were male. The mean age of the patients was 38.7 (range, 19 to 76) years, and 36.9% of the patients were 30 to 39 years old. Of the
127 patients being assessed, 118 were on HAART and 9 were not. The mean CD4+ count was 266.7 ± 209.1 cells/μL. The route of HIV infection was documented in 56 patients (44.1%) with the most common route being homosexual contact in 40 patients (71.4%), followed by heterosexual contact in 15 (26.8%). One patient was suspected to have been infected via blood transfusion.

Of the 127 AIDS patients, 61 (48.0%) had ocular manifestations. The incidence of ocular manifestation in males (47.5%) was lower than in females (60.0%), but this difference was not significant (p = 0.585). The mean age of the patients with and without ocular manifestation was 40.1 ± 10.8 and 37.3 ± 12.6 years, respectively (p = 0.172). Ocular manifestations were most common in the 30 to 39 years age group (36.9%), followed by 40 to 49 years (24.6%), and 20 to 29 years (20.0%). However, the differences in the distribution of ocular manifestation between the age groups were not significant (p = 0.240). Patients with ocular manifestations had lower CD4+ counts than patients without ocular manifestations (233.4 vs. 297.4 cells/μL, respectively), but this difference was not significant (p = 0.084) (Table 1).

The incidence of anterior segment manifestations was higher than posterior segment manifestations, at 28.3% and 19.7%, respectively. The mean ± SD CD4+ count for those patients with anterior and posterior segment ocular manifestations was significantly different at 335.9 ± 240.8 and 85.7 ± 80.6, respectively (p < 0.05). Relative frequencies of ocular manifestations differed in patients grouped according to the CD4+ counts. Specifically, anterior segment manifestations were common in patients with CD4+ counts of 200 to 499 cells/μL (58.3%), while posterior segment manifestations were common in patients with CD4+ counts <200 cells/μL (88.0%) (Fig. 2).

Anterior segment and adnexal ocular manifestations were seen in 36 patients (28.3%). The most common anterior segment ocular manifestation was keratoconjunctivitis sicca, which was seen in 14.2% of the patients, followed by conjunctival microvasculopathy (9.4%) and herpes zoster ophthalmicus (2.4%). The majority of patients with anterior segment ocular manifestations (58.3%) had CD4+ counts of 200 to 499 cells/μL. Keratoconjunctivitis sicca and conjunctival microvasculopathy were also common in patients with CD4+ counts of 200 to 499 cells/μL (Table 2).

Posterior segment ocular manifestations were seen in 25 patients (19.7%). Retinal microvasculopathy was seen in 19 patients (15.0%), followed by CMV retinitis (3.1%), branch retinal vein occlusion (0.8%), and optic neuritis (0.8%). One patient had retinal detachment present at the time of diagnosis of CMV retinitis. Retinal microvasculopathy and CMV retinitis were common in patients with CD4+ counts <200 cells/μL. Other ocular manifestations, neoplasms, or opportunistic infections such as progressive outer retinal

Table 1. Demographic characteristics and ocular manifestations of human immunodeficiency virus-infected or acquired immunodeficiency syndrome patients

| Demographic characteristics | Ocular manifestations | No ocular manifestations | p-value |
|-----------------------------|-----------------------|--------------------------|--------|
| Sex (male / female, % male) | 58 / 3 (95.1)         | 64 / 2 (97.0)            | 0.585* |
| Age (yr, range)             | 40.1 ± 10.8 (22-68)   | 37.3 ± 12.6 (19-77)      | 0.172† |
| Age group (yr)              |                       |                          | 0.240‡ |
| 10-19                       | 0 (0.0)               | 1 (1.5)                  |        |
| 20-29                       | 12 (19.6)             | 19 (28.8)                |        |
| 30-39                       | 22 (36.1)             | 24 (36.4)                |        |
| 40-49                       | 15 (24.6)             | 13 (20.0)                |        |
| 50-59                       | 9 (14.8)              | 3 (4.5)                  |        |
| >60                         | 3 (5.0)               | 5 (8.1)                  |        |
| Total                       | 61 (48.0)             | 66 (52.0)                |        |
| CD4+ counts (cells/μL)      | 233.4 ± 227.6         | 297.4 ± 186.8            | 0.084† |

Values are presented as number (%) or mean ± standard deviation unless otherwise indicated.
*Chi-square test; †Student’s t-test; ‡Fisher’s exact test.

Fig. 2. Relative frequencies (percentages) of ocular manifestations in patients grouped according to the CD4+ counts. *p < 0.05; †p < 0.01, chi-square test.
Multiple logistic regression was performed using variables that were significantly associated with the presence of ocular manifestations. Patients with CD4+ counts <200 cells/μL were more likely to have ocular manifestations than patients with CD4+ counts ≥200 cells/μL (p = 0.041; adjusted odds ratio [OR] = 2.228; 95% confidence interval [CI], 1.032 to 4.810). Patients >35 years old were more likely to have ocular manifestations than patients age 35 years (p = 0.041; adjusted OR = 2.177; 95% CI, 1.033 to 4.586). Notably, there were no significant associations between ocular manifestations and sex or HAART (p > 0.05) (Table 3).

Table 2. Distribution of the ocular manifestations and CD4+ counts among human immunodeficiency virus-infected or acquired immunodeficiency syndrome patients

| Ocular manifestation | CD4+ counts (cells/μL) | Total |
|----------------------|------------------------|-------|
|                      | 0-199 | 200-499 | 500+ |
| Anterior segment*    |       |         |      |
| Keratoconjunctivitis sicca | 4 (22.2) | 9 (50.0) | 5 (27.8) | 18 (14.2) |
| Conjunctival microvasculopathy | 4 (33.3) | 8 (66.7) | 0 (0.0) | 12 (9.4) |
| Herpes zoster ophthalmicus | 1 (33.3) | 1 (33.3) | 1 (33.3) | 3 (2.4) |
| Blepharitis         | 0 (0.0) | 2 (100.0) | 0 (0.0) | 2 (1.6) |
| Uveitis             | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (0.8) |
| Posterior segment   |       |         |      |
| Retinal microvasculopathy | 18 (94.7) | 1 (5.3) | 0 (0.0) | 19 (15.0) |
| Cytomegalovirus retinitis | 3 (75.0) | 1 (25.0) | 0 (0.0) | 4 (3.1) |
| Branch retinal vein occlusion | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (0.8) |
| Optic neuritis      | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (0.8) |

Values are presented as number (%).
*Anterior segment includes adnexal and external ocular manifestations.

Table 3. Multivariate analysis of risk factors for ocular manifestations in human immunodeficiency virus-infected or acquired immunodeficiency syndrome patients

| Risk factor | Ocular manifestation | Adjusted OR | 95% CI | p-value* |
|-------------|----------------------|-------------|--------|----------|
| Sex         |                      |             |        |          |
| Male        | Yes                  | 58 (47.5)   | 64 (52.5) | 1.347 | 0.200-9.057 | 0.759 |
| Female      | Yes                  | 3 (60.0)    | 2 (40.0) |          |        |        |
| Age (yr)    |                      |             |        |          |
| >35         | Yes                  | 41 (57.0)   | 31 (43.1) | 2.177 | 1.033-4.586 | 0.041 |
| ≤35         | Yes                  | 20 (36.4)   | 35 (63.6) |          |        |        |
| HAART       |                      |             |        |          |
| Yes         | Yes                  | 58 (49.2)   | 60 (50.8) | 1.132 | 0.458-2.796 | 0.788 |
| No          | Yes                  | 3 (33.3)    | 6 (66.7) |          |        |        |
| CD4+ count  |                      |             |        |          |
| <200 cells/μL | Yes                  | 31 (59.6)   | 21 (40.4) | 2.228 | 1.032-4.810 | 0.041 |
| ≥200 cells/μL | Yes                  | 30 (40.0)   | 45 (60.0) |          |        |        |

Values are presented as number (%); Adjusted for sex, age, CD4+ count, and HAART.
OR = odds ratio; CI = confidence interval; HAART = highly active antiretroviral therapy.
*Multiple logistic regression.

Discussion

The overall incidence of ocular manifestations in this study was higher than in other studies performed in Asia, which had ranged from 15.8% to 45.0% [8,21-29]. This difference is likely due to the spectrum of ocular manifesta-
tions considered, as most articles did not include anterior segment manifestations such as keratoconjunctivitis sicca and conjunctival microvasculopathy. As the general health of individuals with HIV infection improves, the evaluation and management of disorders such as keratoconjunctivitis sicca and blepharitis, which were previously overshadowed by more severe, blinding disorders, may demand increased attention.

Keratoconjunctivitis sicca appears to be more common among individuals with AIDS (16.9% to 38.8%) [30-32]. Prevailing theories of its pathogenesis implicate HIV itself as the inflammatory mediator that destroys primary and accessory lacrimal glands. Direct infection and damage to the conjunctiva may also be involved [15]. Blepharitis is also common in HIV-infected individuals, and blepharitis and an eyelid ulcers have been reported to be the initial manifestations of HIV disease in some patients [33]. The pathogenesis of blepharitis in immunodeficient individuals may either involve a reduced ability to control normal flora or more complex changes in cutaneous glands of the eyelids that occur with immunosuppression [34].

The use of HAART seeks to inhibit the progression to AIDS and to prevent death by reducing plasma HIV RNA to sustained low levels, thereby bolstering immunity [35]. An enhanced immune function has been documented in the form of decreased HIV-associated opportunistic infections with associated reductions in ocular morbidity. Contrary to its effect on many other ocular HIV/AIDS-related diseases, HAART has not played a part in significantly reducing the prevalence of keratoconjunctivitis sicca. According to a recent study, 17.8% of HIV-infected individuals given HAART still presented with keratoconjunctivitis sicca after treatment [35].

With HAART, patients are less likely to be affected by blinding posterior segment infections. However, attention should be paid to minor problems requiring ophthalmic care, including anterior segment and external ocular manifestations, which can affect the quality of life [2]. In this study, the incidence of anterior segment manifestations was higher than that of posterior segment manifestations. The most common anterior segment ocular manifestation was keratoconjunctivitis sicca, followed by conjunctival microvasculopathy, comprising a significant portion of the overall incidence. The incidence of keratoconjunctivitis sicca was similar to that in other studies, 21% in the pre-HAART era [31] and 17.8% in the post-HAART era [35]. However, the incidence of conjunctival microvasculopathy was much lower than in studies performed in the pre-HAART era (75%) [9,36-38]. Contrary to its effect on many other ocular HIV/AIDS-related diseases, HAART has not significantly reduced the incidence of keratoconjunctivitis sicca [39].

The most common ocular manifestation in this study was retinal microvasculopathy. The incidence of retinal microvasculopathy was similar to that in previous studies (8% to 12.6%) [8,21-29]. However, the incidence of CMV retinitis was lower than the 5.3% to 20.8% reported in other studies [8,21-29]. Before the HAART era, CMV retinitis was diagnosed in 10% to 45% of patients with late-stage AIDS, and some autopsy series documented CMV in up to 90% of patients [40-43]. By contrast, in the HAART era, there has been an estimated 80% decrease in the incidence of CMV retinitis [44]. The use of HAART has decreased plasma levels of HIV RNA and increased CD4+ counts, improving immune function of patients with HIV infection [45-47]. Immune recovery uveitis was first described in 1998 as a consequence of rapid immune reconstitution after the use of HAART in HIV patients [48]. It is characterized by the development of intraocular inflammation, cystoid macular edema, epiretinal membrane, and vitritis. However, there were no cases of immune recovery uveitis in our series.

In this study, the mean CD4+ count was significantly lower in patients with posterior segment ocular manifestations compared to anterior segment ocular manifestations. Posterior segment ocular manifestations were common in patients with CD4+ counts <200 cells/μL. It is known that the prevalence of retinal microvasculopathy is inversely proportional to the CD4+ count, and CMV retinitis is common in patients whose CD4+ counts are <50 cells/μL [49]. However, anterior segment manifestations were common in patients with CD4+ counts of 200 to 499 cells/μL. Keratoconjunctivitis sicca is not related to the CD4+ count or associated with the severity of HIV [50]. Conjunctival microvasculopathy was also common in patients with CD4+ counts <100 cells/μL [51]. Conversely, no correlation between CD4+ count and conjunctival microvasculopathy has been reported [52]. In this study, both keratoconjunctivitis sicca and conjunctival microvasculopathy were common in patients with CD4+ counts of 200 to 499 cells/μL.

In this study, CD4+ counts <200 cells/μL and age >35 years were independent risk factors for developing ocular
manifestations, with CD4+ counts <200 cells/μL being a well-established risk factor [53]. Age >35 years was found to be an independent risk factor for developing ocular manifestations [54]. One idea behind this difference between age groups is that age may actually affect patient immunity.

One limitation of the present study is that we diagnosed keratoconjunctivitis sicca using only a subjective index, the OSDI questionnaire. Recently, ocular surface staining scores by the Oxford system [55], tear film breakup time, and the Schirmer-1 test scores were used as objective signs for diagnosing keratoconjunctivitis sicca. Another limitation of our study is its small population of AIDS patients not on HAART.

In conclusion, this study demonstrated that the introduction of HAART has changed the landscape of ocular presentations. The incidence of anterior segment and external ocular manifestations was higher than posterior segment manifestations, and the most common ocular manifestation in this study was retinal microvasculopathy, followed by keratoconjunctivitis sicca and conjunctival mirovasculopathy. Posterior segment manifestations were common in patients with CD4+ counts <200 cells/μL, while anterior segment manifestations were common in patients with CD4+ counts of 200 to 499 cells/μL. Age >35 years was also found to be an independent risk factor for developing ocular manifestations.

Conflict of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgements

This work was supported by the Soonchunhyang University Research Fund.

References

1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-31.
2. Jeng BH, Holland GN, Lowder CY, et al. Anterior segment and external ocular disorders associated with human immunodeficiency virus disease. Surv Ophthalmol 2007;52:329-68.
3. Moraes HV Jr. Ocular manifestations of HIV/AIDS. Curr Opin Ophthalmol 2002;13:397-403.
4. Vrabec TR. Posterior segment manifestations of HIV/AIDS. Surv Ophthalmol 2004;49:131-57.
5. Shah SU, Kerkar SP, Pazare AR. Evaluation of ocular manifestations and blindness in HIV/AIDS patients on HAART in a tertiary care hospital in western India. Br J Ophthalmol 2009;93:88-90.
6. Hodge WG, Seiff SR, Margolis TP. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology 1998;105:895-900.
7. Kestelyn PG, Cunningham ET Jr. HIV/AIDS and blindness. Bull World Health Organ 2001;79:208-13.
8. Lai TY, Wong RL, Luk FO, et al. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era. Clin Experiment Ophthalmol 2011;39:99-104.
9. Shuler JD, Engstrom RE Jr, Holland GN. External ocular disease and anterior segment disorders associated with AIDS. Int Ophthalmol Clin 1989;29:98-104.
10. Rodrigues ML, Rodrigues Mde L, Figueiredo JF, de Freitas JA. Ocular problems in Brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era. Braz J Infect Dis 2007;11:199-202.
11. Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina 2005;25:633-49.
12. Hogg RS, O’Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
13. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000;118:615-21.
14. Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol 2010;128:94-101.
15. Acharya NR, Cunningham ET Jr. Corneal, anterior segment, and adnexal manifestations of human immunodeficiency virus. Int Ophthalmol Clin 1998;38:161-77.
16. Biswas J, Fogla R, Gopal L, et al. Current approaches to di-
agnosis and management of ocular lesions in human immunodeficiency virus positive patients. *Indian J Ophthalmol* 2002;50:83-96.
17. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. *Am J Ophthalmol* 1984;97:133-42.
18. Henderly DE, Freeman WR, Smith RE, et al. Cytomegalovirus retinitis as the initial manifestation of the acquired immune deficiency syndrome. *Am J Ophthalmol* 1987;103(3 Pt 1):316-20.
19. Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. *Am J Ophthalmol* 1982;93:393-402.
20. Jabs DA. Ocular manifestations of HIV infection. *Trans Am Ophthalmol Soc* 1995;93:623-83.
21. Ausayakhun S, Watananikorn S, Iritipunkul N, et al. Epidemiology of the ocular complications of HIV infection in Chiang Mai. *J Med Assoc Thai* 2003;86:399-406.
22. Chiou SH, Liu CY, Hsu WM, et al. Ophthalmic findings in patients with acquired immunodeficiency syndrome. *J Microbiol Immunol Infect* 2000;33:45-8.
23. Gharai S, Venkatesh P, Garg S, et al. Ophthalmic manifestations of HIV infections in India in the era of HAART: analysis of 100 consecutive patients evaluated at a tertiary eye care center in India. *Ophthalmic Epidemiol* 2008;15:264-71.
24. Kim SJ, Park SJ, Yu HG, et al. Ocular manifestations of acquired immunodeficiency syndrome in Korea. *J Korean Med Sci* 2012;27:542-6.
25. Lin YC, Yang CH, Lin CP, et al. Cytomegalovirus retinitis and immune recovery uveitis in AIDS patients treated with highly active antiretroviral therapy in Taiwanese. *Ocul Immunol Inflamm* 2008;16:83-7.
26. Miyamoto C, Yashiro S, Nagata Y, Nagataki S. Ocular complications in patients infected with human immunodeficiency virus seen at the Acquired Immunodeficiency Syndrome Clinical Center. *Nihon Ganka Gakkai Zasshi* 2001;105:483-7.
27. Pathai S, Deshpande A, Gilbert C, Lawn SD. Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional study. *BMC Infect Dis* 2009;9:158.
28. Uemura A, Yashiro S, Takeda N, Oka S. Ocular complications in patients with human immunodeficiency virus infection. *Nihon Ganka Gakkai Zasshi* 2006;110:698-702.
29. Wang J, You Q, Yang H, et al. Retinal findings in Chinese patients with HIV infection. *Ophthalmic Res* 2008;40:98-100.
30. DeCarlo DK, Penner SL, Schamerloh RJ, Fullard RJ. Dry eye among males infected with the human immunodeficiency virus. *J Am Optom Assoc* 1995;66:533-8.
31. Lucca JA, Farris RL, Bielory L, Caputo AR. Keratoconjunctivitis sicca in male patients infected with human immunodeficiency virus type 1. *Ophthalmology* 1990;97:1008-10.
32. Lucca JA, Kung JS, Farris RL. Keratoconjunctivitis sicca in female patients infected with human immunodeficiency virus. *CLAO J* 1994;20:49-51.
33. Biswas J, Madhavan HN, Kumarasamy N, Solomon S. Blepharitis and lid ulcer as initial ocular manifestation in acquired immunodeficiency syndrome patients. *Indian J Ophthalmol* 1997;45:233-4.
34. Friedlaender MH, Masi RJ, Osumoto M, et al. Ocular microbial flora in immunodeficient patients. *Arch Ophthalmol* 1980;98:1211-3.
35. Kahraman G, Krepler K, Franz C, et al. Seven years of HAART impact on ophthalmic management of HIV-infected patients. *Ocul Immunol Inflamm* 2005;13:213-8.
36. Teich SA. Conjunctival vascular changes in AIDS and AIDS-related complex. *Am J Ophthalmol* 1987;103(3 Pt 1):332-3.
37. Engstrom RE Jr, Holland GN, Hardy WD, Meiselman HJ. Hemorheologic abnormalities in patients with human immunodeficiency virus infection and ophthalmic microvascularopathy. *Am J Ophthalmol* 1990;109:153-61.
38. Geier SA, Klauss V, Goebel FD. Ocular microangiopathic syndrome in patients with acquired immunodeficiency syndrome and its relationship to alterations in cell adhesion and in blood flow. *Ger J Ophthalmol* 1994;3:414-21.
39. Ali R, Kim JY, Henderson BA. Adnexal and anterior segment manifestations of HIV/AIDS. *Int Ophthalmol Clin* 2007;47:15-32.
40. d'Arminio Monforte A, Mainini F, Testa L, et al. Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. *AIDS* 1997;11:517-24.
41. Drew WL. Cytomegalovirus infection in patients with AIDS. *Clin Infect Dis* 1992;14:608-15.
42. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated
with zidovudine. The Zidovudine Epidemiology Study Group. *J Infect Dis* 1992;166:1223-7.
43. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. *N Engl J Med* 1993;329:1922-6.
44. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;338:853-60.
45. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. *N Engl J Med* 1996;334:1011-7.
46. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N Engl J Med* 1997;337:725-33.
47. Robinson MR, Reed G, Csaky KG, et al. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. *Am J Ophthalmol* 2000;130:49-56.
48. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. *Arch Ophthalmol* 1998;116:169-75.
49. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. *Am J Ophthalmol* 1993;115:575-82.
50. Geier SA, Libera S, Klauss V, Goebel FD. Sicca syndrome in patients infected with the human immunodeficiency virus. *Ophthalmology* 1995;102:1319-24.
51. Turner BJ, Hecht FM, Ismail RB. CD4+ T-lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1: a review for clinical practitioners. *Arch Intern Med* 1994;154:1561-73.
52. Ambiya V, Sagar A, Patyal S, Mohanty AP. Ocular manifestations in 321 male consecutive cases of human immunodeficiency virus/acquired immunodeficiency syndrome at an HIV-referral centre. *Med J Armed Forces India* 2012;68:214-21.
53. Ndoye NB, Sow PS, Ba EA, et al. Ocular manifestations of AIDS in Dakar. *Dakar Med* 1993;38:97-100.
54. Bekele S, Gelaw Y, Tessema F. Ocular manifestation of HIV/AIDS and correlation with CD4+ cells count among adult HIV/AIDS patients in Jimma town, Ethiopia: a cross sectional study. *BMC Ophthalmol* 2013;13:20.
55. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. *Cornea* 2003;22:640-50.